Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals (CRNX) has granted non-qualified stock options to sixteen new non-executive employees under its 2021 Employment Inducement Incentive Award Plan. The options allow purchase of 146,400 shares at an exercise price of $57.17 per share, matching CRNX's closing price on Nasdaq Global Select Market on December 10, 2024. The stock options will vest over four years, with 25% vesting after one year and the remainder vesting in 36 monthly installments, contingent on continued employment. These grants comply with Nasdaq Listing Rule 5635(c)(4) as inducement awards for new employees.
Crinetics Pharmaceuticals (CRNX) ha concesso opzioni su azioni non qualificate a sedici nuovi dipendenti non esecutivi nell'ambito del suo Piano di Incentivazione per l'Occupazione 2021. Le opzioni consentono l'acquisto di 146.400 azioni a un prezzo di esercizio di 57,17 $ per azione, che corrisponde al prezzo di chiusura di CRNX sul Nasdaq Global Select Market del 10 dicembre 2024. Le opzioni azionarie matureranno nell'arco di quattro anni, con il 25% che matura dopo un anno e il resto che matura in 36 rate mensili, a condizione del continuato impiego. Questi conferimenti sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4) come premi di incentivazione per nuovi dipendenti.
Crinetics Pharmaceuticals (CRNX) ha otorgado opciones sobre acciones no calificadas a dieciséis nuevos empleados no ejecutivos bajo su Plan de Incentivos para la Contratación de 2021. Las opciones permiten la compra de 146.400 acciones a un precio de ejercicio de $57.17 por acción, que coincide con el precio de cierre de CRNX en el Nasdaq Global Select Market del 10 de diciembre de 2024. Las opciones sobre acciones se consolidarán durante cuatro años, con el 25% consolidándose después de un año y el resto consolidándose en 36 pagos mensuales, dependiendo del empleo continuo. Estas concesiones cumplen con la Regla 5635(c)(4) de cotización de Nasdaq como premios de inducimiento para nuevos empleados.
크리네틱스 파마슈티컬스 (CRNX)는 16명의 신입 비임원 직원에게 2021년 고용 유인을 위한 인센티브 상여금 계획에 따라 비정상 주식 옵션을 부여했습니다. 이 옵션은 146,400주를 주당 $57.17의 행사 가격으로 구매할 수 있도록 하며, 2024년 12월 10일 Nasdaq Global Select Market에서 CRNX의 종가와 일치합니다. 주식 옵션은 4년 동안 만료되며, 1년 후 25%가 만료되고 나머지는 계속 고용되는 조건으로 36회의 월별 분할로 만료됩니다. 이러한 부여는 신입 직원에 대한 유인상으로서 Nasdaq 상장 규칙 5635(c)(4)에 부합합니다.
Crinetics Pharmaceuticals (CRNX) a accordé des options d'achat d'actions non qualifiées à seize nouveaux employés non exécutifs dans le cadre de son Plan d'Incitation à l'Emploi 2021. Les options permettent d'acheter 146.400 actions à un prix d'exercice de 57,17 $ par action, correspondant au prix de clôture de CRNX sur le Nasdaq Global Select Market le 10 décembre 2024. Les options seront acquises sur une période de quatre ans, avec 25 % acquises après un an et le reste acquérant en 36 versements mensuels, sous réserve de l'emploi continu. Ces attributions sont conformes à la Règle d'inscription Nasdaq 5635(c)(4) en tant que récompenses d'incitation pour les nouveaux employés.
Crinetics Pharmaceuticals (CRNX) hat nicht qualifizierte Aktienoptionen an sechzehn neue nicht-executive Mitarbeiter im Rahmen ihres Anreizprogramms für Beschäftigung 2021 gewährt. Die Optionen ermöglichen den Kauf von 146.400 Aktien zu einem Ausübungspreis von 57,17 $ pro Aktie, was dem Schlusskurs von CRNX an der Nasdaq Global Select Market am 10. Dezember 2024 entspricht. Die Aktienoptionen werden über vier Jahre hinweg ausgeübt, wobei 25% nach einem Jahr fällig werden und der Rest in 36 monatlichen Raten, abhängig von der fortgesetzten Beschäftigung. Diese Gewährungen entsprechen der Nasdaq-Listungsregel 5635(c)(4) als Anreizpreise für neue Mitarbeiter.
- Company's ability to attract new talent with equity compensation
- Stock price at $57.17 indicates strong market valuation
- Potential future dilution from 146,400 new shares
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2024, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 146,400 shares of its common stock to sixteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2021 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 450-6464
FAQ
How many shares were granted in CRNX's December 2024 inducement awards?
What is the exercise price for CRNX's December 2024 inducement stock options?
What is the vesting schedule for CRNX's December 2024 inducement grants?
How many new employees received CRNX stock options in December 2024?
